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There are few markers for which there is a sufficiently high
level of evidence to justify their use in clinical decision
making. In order to reach such levels, the evidence must
address a specific utility, such as prognosis or prediction, so
that the outcome of a patient in one state designated by the
marker (for example, a patient with a negative test result)
would be so different from that in another patient in a different
state (for example, a patient with a positive test result) that
she (or he) would accept a different treatment recommen-
dation. Many assume that a marker is used to determine
whether to treat a patient with a given therapeutic agent.
However, and especially with regard to treatments with
relatively low toxicity and high impact such as endocrine
treatments, the question is usually ‘Will there be so little
benefit from the treatment that she is willing to forego this
therapy to avoid toxicities?’ The level of evidence that would
drive use of a marker must be such that estimates of outcome
differences are reliable. Reliable estimates are a function of
rigorous technical development to ensure analytical accuracy,
appropriate study design to address the chosen utility, and
sophisticated data analysis (including independent validation)
so that one may be certain that the confidence limits of the
estimates are narrow.
Endocrine therapy has been a mainstay of treatment of breast
cancer since the late 1800s [1], and it has led to remarkable
palliation, mortality reduction and even prevention in women
with or at risk for this disease. A breast cancer can be either
oestrogen independent (and therefore refractory to all endo-
crine treatments) or endocrine dependent but resistant to
specific endocrine strategies and even to specific agents.
Because endocrine therapy is expensive and may be
associated with frequent bothersome and occasionally life-
threatening toxicities, a marker of either absolute endocrine
independence or resistance to specific therapies would be
remarkably valuable in caring for women with breast cancer.
Of course, the oestrogen receptor (ER) represents such a
marker. ER was first identified by Jensen and colleagues [2].
Very soon afterward, McGuire and colleagues [3-5] showed
that although prediction of resistance was not absolute,
women with ER-negative or low metastatic breast cancers
were very unlikely to respond to a variety of anti-oestrogen
therapies. Subsequent meta-analyses conducted by the Early
Breast Cancer Trialists’ Collaborative Group (the Oxford
Overview) [6] confirmed nearly complete lack of benefit from
adjuvant tamoxifen in ER-negative patients. Indeed, ER is one
of the few tumour markers recommended by the Tumor
Marker Guidelines Committee of the American Society of
Clinical Oncology for routine use in the evaluation and
treatment of patients with breast cancer [7].
Although it is highly unlikely that patients with ER-negative
tumours will benefit from endocrine treatment, only 50% to
60% of those with ER-positive, or rich, breast cancers will.
This observation raises a critical question regarding the
technical and biological accuracy of ER measurement. Early
assays of ER were performed using ligand (oestradiol)-
binding assays (LBAs), which are technically difficult, require
relatively large amounts of fresh, frozen tissue, and can be
complicated by prolonged delays to freezing and variable
amounts of cancer within the tissue. In the late 1980s,
polyclonal and monoclonal antibodies to ER became avail-
able, permitting immunohistochemical evaluation of ER in
fixed tissue with in situ assessment of whether the cancer
cells themselves were positive or negative. However,
surprisingly, the ability of immunohistochemistry to predict
benefit from various endocrine therapies has never been as
well vetted as that of the LBAs. Rather, correlative studies
demonstrating relative immunohistochemical scores with LBA
results were reported, and a variety of issues regarding the
technical components of immunohistochemistry and
correlation with clinical outcomes have never been addressed
properly. Indeed, the American Society of Clinical Oncology
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has partnered with the College of American Pathologists to
establish guidelines and proficiency testing for evaluation of
another critical marker, human epidermal growth factor
receptor (HER)2 [8], and a similar initiative is planned for ER
in the future.
A variety of candidate markers have been proposed that
might complement and further refine the predictive utility of
ER. To start, simple quantitative analysis of ER might provide
additional information. Indeed, in protocol B14, in which
patients were randomly assigned to adjuvant tamoxifen or
placebo, the National Adjuvant Bowel and Breast Project
reported a stepwise additional benefit from increasing deciles
of ER content when measured by LBA (S Paik, personal
communication). However, even patients with very low ER
levels seem to benefit from tamoxifen [9]. In addition to ER,
other potential factors include ER-β, progesterone receptor
(PR), ER co-activating and repressing proteins, the epithelial
growth factor receptor family, and various markers of cell
survival and proliferation. Of these, perhaps PR and HER2
are the most intensively studied. Preclinical and preliminary
clinical studies strongly suggested that absence of PR and/or
elevated expression of HER2 are associated with either
relative resistance to all endocrine therapies or specific
resistance to certain types (such as selective ER modulators,
for example tamoxifen) but ongoing sensitivity to other
strategies (such as oestrogen depletion with aromatase
inhibitors [AIs] in postmenopausal women). To summarize a
great deal of literature, it is not clear that either marker
contributes to decision making regarding endocrine treatment
in women with ER-positive breast cancer. Although low PR
and high HER2 levels are consistently associated with worse
prognosis, neither of these conditions preclude endocrine
treatment in a patient with ER-positive breast cancer, and
results regarding selection of tamoxifen versus an AI with
these markers have been inconsistent [10-14].
PR may be helpful in selecting ER-negative patients who
might benefit from tamoxifen [10]. ER-negative/PR-positive
tumours are uncommon, and this utility remains controversial.
Nonetheless, it seems prudent to recommend endocrine
treatment in this setting, in order to avoid under-treatment
with such a highly effective and relatively low toxicity strategy.
Recent technological advances have permitted analysis of
expression of several genes simultaneously, resulting in a
‘profile’ or ‘signature’ pattern [15]. Although several of these
appear to provide prognostic information, only a few have
been tested specifically to determine their clinical utility as a
predictor of outcome in patients treated with endocrine
therapy [16,17]. Of these, the 21-gene recurrence score
(RS; OncotypeDX, Genomics Health Inc., Redwood City, CA,
USA) incorporates semi-quantitative analysis of ER and
downstream genes, HER2 and associated genes, a number
of proliferation genes, and selected genes that are ostensibly
related to cell survival and metastatic potential, using a
multiparameter assay based on RT-PCR [18]. Using archived,
formalin-fixed, paraffin-embedded tissues, the National
Surgical Adjuvant Breast and Bowel Project investigators
have reported that approximately 50% of patients with node-
negative, ER-positive (as determined by LBA) breast cancer
treated with only tamoxifen have low RS. These patients have
a remarkably favourable prognosis over 10 years, whereas
the remaining 50% of patients fall into the intermediate or
high RS categories, with consequent less favourable out-
comes [17,19]. Moreover, in exploratory analyses this assay
appeared to be predictive of benefit from tamoxifen (low RS
predicts benefit and high RS predicts resistance) and from
chemotherapy (low RS predicts resistance and high RS
predicts benefit) [19,20].
Finally, recently reported results have suggested that
inherited, germ-line factors may also explain differential
benefit and toxicity between patients treated with endocrine
therapies. In particular, inherited single nucleotide polymor-
phisms (SNPs) in CYP2D6 result in poor conversion of the
relatively inactive parent compound, tamoxifen, into its most
active metabolite, endoxifen [21-23]. Although controversial,
some studies have suggested that patients with these SNPs
may have a worse outcome than those with wild-type
CYP2D6 when treated with tamoxifen [24]. Likewise, SNPs
in the genes that encode ER-α and ER-β (ESR1 and ESR2)
may also modulate the nontumoural effects of tamoxifen on
lipid levels, hot flushes and bone mineral density [25,26], and
SNPs in the gene that encodes aromatase (CYP19) may
affect the activities of various AIs [27].
In summary, ER is clearly a potent and important predictive
factor that should be evaluated and used, in each patient with
breast cancer, to determine whether endocrine treatment is
appropriate. Other putative markers of endocrine resistance
in ER-positive cancers, although supported by strong
preclinical data, have not yet achieved a sufficient level of
evidence that one should withhold potentially life-saving and
beneficial therapy based on their results.
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